Dr. Matthew Porteus is a distinguished physician-scientist at Stanford University who is helping advance the future of genetic medicine. His research focuses on developing gene-editing technologies that could correct inherited diseases at their genetic source, offering new possibilities for patients with conditions such as sickle cell disease, thalassemia, and immune system disorders.
Porteus serves as the Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University School of Medicine. He is also a pediatric hematologist whose work combines laboratory discoveries with clinical research aimed at developing long-lasting treatments for children with serious genetic conditions.

Education and Medical Career
Porteus grew up in California and completed his undergraduate education at Harvard University. He subsequently earned both his MD and PhD from Stanford University. His medical training included pediatric residency at Boston Children’s Hospital and a fellowship in pediatric hematology and oncology.
Early in his research career, he became interested in correcting disease-causing genetic mutations in blood-forming stem cells. This interest eventually developed into a major research program focused on genome editing.
His work has helped establish important approaches for modifying human cells, particularly using technologies that allow scientists to make precise changes to DNA.
Advancing Gene Editing Research
One of Porteus’s major research interests is developing treatments that correct genetic mutations rather than simply managing their effects.
His laboratory investigates ways to use gene-editing tools, including CRISPR-based technologies, to repair faulty genes in a patient’s own blood-forming stem cells. These cells are important because they can produce different types of blood and immune cells throughout a person’s life.
This approach could eventually provide lasting treatment options for inherited conditions that currently require ongoing medical care.
Important Developments in 2026
In February 2026, Stanford reported that Porteus and his research team had developed a hematopoietic stem cell gene-editing approach with potential applications across HIV and a range of inherited genetic diseases.
The research is particularly significant because gene-edited stem cells could potentially rebuild parts of a patient’s blood and immune system with corrected cells.
Stanford also announced a collaboration with biotechnology company Cellares to explore automated manufacturing and testing processes for these therapies. Improving manufacturing consistency and scalability is an important step toward making advanced treatments more accessible.

Looking Ahead
Porteus continues to lead research at Stanford’s Center for Definitive and Curative Medicine. His work reflects a growing shift in healthcare toward treatments that address the underlying causes of disease.
By combining pediatric medicine, molecular biology, and advanced genetic technologies, Dr. Matthew Porteus is helping develop a future in which some inherited diseases may be treated at their source rather than managed throughout a patient’s lifetime.




